

APPLICATION DATA SHEET

Application Information

Application number:	Not yet assigned
Filing Date:	Herewith
Application Type:	Regular
Subject Matter:	Utility
Suggested Group Art Unit:	N/A
CD-ROM or CD-R?:	None
Sequence submission?:	None
Computer Readable Form (CRF)?:	No
Title:	✓ ASSAY FOR THE SCREENING OF COMPOUNDS ACTING THROUGH ERBB-2
Attorney Docket Number:	100873-1P US
Request for Early Publication?:	No
Request for Non-Publication?:	No
Small Entity?:	No
Petition included?:	No
Secrecy Order in Parent Application?:	No

Applicant Information

Applicant Authority Type:	Inventor
Primary Citizenship Country:	United Kingdom
Status:	✓ Full Capacity
Given Name	✓ Daniel Mark
Family Name:	Hickinson
City of Residence:	Macclesfield
Country of Residence:	United Kingdom
Street of mailing Address:	AstraZeneca R & D Alderley Alderley Park, Macclesfield
City of mailing address:	Macclesfield
Country of mailing address:	United Kingdom
Postal or Zip Code of mailing address:	SK10 4TG

Correspondence Information

Correspondence Customer Number 44992

Representative Information

Lucy C. Padget (Limited Recognition Under 37 CFR §11.9(b)), Christine C. McCormack (Limited Recognition Under 37 CFR §10.9(b)) and all practitioners associated with

Representative Customer Number 44992

Domestic Priority Information

Application	Continuity Type	Parent Application	Parent Filing Date
This application	National Stage of	PCT/GB2003/004655	October 28, 2003

Foreign Priority Information

Country	Application No.	Filing Date	Priority Claimed
GB	0225282.3	October 31, 2002	Yes

Assignee Information

Assignee name: AstraZeneca AB
Street of mailing address R&D Headquarters
Global Intellectual Property Patents
City of mailing address: Södertälje
Country of mailing Address Sweden
Postal or Zip Code of mailing address: SE-151 85